Followers | 237 |
Posts | 10817 |
Boards Moderated | 0 |
Alias Born | 07/17/2006 |
Tuesday, May 12, 2020 8:09:11 AM
The killer in playing the stock market is incomplete information..The stock market is risk betting which means you can win..but you can also lose. Most retail stock market players lose money..Most lose all their money in a period less than a year because they are playing against professionals who have more and better information than the retail...But even the best funds with the best strategies can and do lose all their money..Because their strategies (all strategies) can be counter traded. And there are funds that
prey on the weak...
If you "play the market" you need to take responsibility for your own mistakes...Two years ago JT was an all star...Tom Brady, Larry Bird and Bobby Orr all thrown together..Now he is a bumbling idiot. He should have settled...Well we to this day do not know if he tried to settle. What we do know is he reached a settlement with TEVA...Does it not make sense he would have made overtures to Reddi and Hickma...Maybe they just were more confident than TEVA..We just do not know..But more to the point..You and I as shareholders, did not need JT's permission to hedge the DC's decision..We individuals made that decision..Not JT...
Actually in terms of the bet being asymmetrical...It was a no brainer. The PPS was double digits and an unfavorable decision would have definitely sent the price down below $5...So why did so many of us (self included), not hedge the bet. THE REASON WAS.. WE ALL THOUGHT THE DECISION WAS A VIRTUAL CERTAINTY CONSIDERING AMARIN'S ALL STAR LAWYERS AND THE ISSUES. We just never considered we would get a Judge Du for the trial..
The hedge this time around is not so clearcut. The PPS is in the mid single digit range, a win for Amarin would likely result in the PPS to go into the low twenties...A loss and we would essentially be in the same position we find ourselves in today..The PPS would be a knee jerk drop into high 4's or low 5's...With a gradual return to today's prices..
All this ranting and raving about how JT screwed up is just hind sight. Looking for the culprit...Go look in the mirror..When to hedge and not to hedge is based on estimating what the effect on the price the event is going to have...Often times there is going to be a small difference one way and a very large one the other. And that should determine whether or not to hedge and not your gut feeling on which way the the event is going to go..
Finally if you play the market...you have to take responsibility for your own mistakes...As the real Jesse Livermore pointed out..If a man did not make mistakes he would own the world in a couple of months..The mistake family is a very big one..We all make them..Step one..take responsibility..If you always have somebody you can blame..How are you ever going to learn...
":>) JL
Recent AMRN News
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
- Amarin Chairman & CEO Issue Letter to Shareholders • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM